Clinical Effects of Colesevelam in Hispanic Subjects with Primary Hyperlipidemia and Prediabetes

References

• . International Diabetes Federation. IDF Diabetes Atlas; Central and South America. 2009. http://www.idf.org/diabetesatlas/south-and-central-america. Accessed August 18, 2011
   Google Scholar
• . Cowie CC, Rust KF, Ford ES, . Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32(2):287–294
   PubMed Web of Science ®Google Scholar
• . Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884–1890
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care. 2012;35( suppl 1):S11–S63
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Blonde L, Braithwaite SS, ; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13 ( suppl 1):1–68
   PubMedGoogle Scholar
• . Willey JZ, Rodriguez CJ, Carlino RF, . Race-ethnic differences in the association between lipid profile components and risk of myocardial infarction: The Northern Manhattan Study. Am Heart J. 2011;161(5):886–892
   PubMedGoogle Scholar
• . Handelsman Y, Mechanick JI, Blonde L, ; AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17( suppl 2):1–53
   PubMedGoogle Scholar
• . Edelstein SL, Knowler WC, Bain RP, . Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46(4):701–710
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Dept of Health and Human Services, Centers for Disease Control and Prevention; 2011
   Google Scholar
• . Knowler WC, Barrett—Connor E, Fowler SE, ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403
   PubMed Web of Science ®Google Scholar
• . Tuomilehto J, Lindström J, Eriksson JG, ; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350
   PubMed Web of Science ®Google Scholar
• . Chiasson JL, Josse RG, Gomis R, ; STOP-NIDDM randomised trial. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–2077
   PubMed Web of Science ®Google Scholar
• . Gerstein HC, Yusuf S, Bosch J, ; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096–1105
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Tripathy D, Schwenke DC, ; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104–1115
   PubMed Web of Science ®Google Scholar
• . Buchanan TA, Xiang AH, Peters RK, . Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51(9):2796–2803
   PubMed Web of Science ®Google Scholar
• . Xiang AH, Peters RK, Kjos SL, . Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55(2):517–522
   PubMed Web of Science ®Google Scholar
• . Handelsman Y, Goldberg RB, Garvey WT, . Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010;16(4):617–628
   PubMed Web of Science ®Google Scholar
• . Jones MR, Mudaliar S, Hernandez—Triana E, . Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Curr Med Res Opin. 2009;25(9):2239–2249
   PubMed Web of Science ®Google Scholar
• . World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. 2006. http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf. Accessed March 21, 2011
   Google Scholar
• . Rosenstock J, Foley JE, Rendell M, . Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31(1):30–35
   PubMed Web of Science ®Google Scholar
• . Garber AJ, Handelsman Y, Einhorn D, . Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008;14(7):933–946
   PubMedGoogle Scholar
• . Ryden L, Standl E, Bartnik M, ; Task Force on Diabetes and Cardiovascular Disesases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136
   PubMed Web of Science ®Google Scholar
• . Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–297
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Abdul—Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol. 2011;108( 3 suppl):3B–24B
   PubMed Web of Science ®Google Scholar